Overview

Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

Status:
Terminated

Trial end date:
2007-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of the CCR5 antagonist GW873140 or placebo in combination with an optimized background regimen in treatment-experienced HIV-infected subjects with R5-tropic virus

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Aplaviroc